Abstract

In previous grant cycles, the ADCS has not played a major role in biomarker measurement; assays for Apolipoprotein E (ApoE) genotype, and for plasma and CSF measurement of amyloid peptides and tau proteins have been subcontracted to companies or external academic labs. However, the importance of biomarker measurement has grown steadily, in part due to the success of the Alzheimer's Disease Neuroimaging Initiative. There have been an increasing number of requests for stored ADCS samples, and increasing requests for biomarker measurement from ADCS investigators. To meet these needs, in late 2008, we established a Biomarker Core which is located on the 3rd floor of the Medical Teaching Facility building at UCSD School of Medicine.

Public Health Relevance

The goal of the laboratory is to identify biomarkers for preclinical AD and better understand how treatment parameters may impact these biomarkers. In addition to playing a role in ADCS clinical trials, another objective of the Biomarker Core is research based and aims to identify and characterize novel biomarkers of AD. The primary focus of this research is on plasma beta-amyloid.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AG010483-24
Application #
8776249
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7)
Project Start
Project End
2016-02-29
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
24
Fiscal Year
2015
Total Cost
$208,935
Indirect Cost
$49,000

  Institution

Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093

  Publications

Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358
Jacobs, Heidi I L; Hedden, Trey; Schultz, Aaron P et al. (2018) Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci 21:424-431
Buckley, Rachel F; Mormino, Elizabeth C; Amariglio, Rebecca E et al. (2018) Sex, amyloid, and APOE ?4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement 14:1193-1203
Raman, Mekala R; Tosakulwong, Nirubol; Zuk, Samantha M et al. (2017) Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. J Hypertens 35:2479-2485
Respondek, Gesine; Kurz, Carolin; Arzberger, Thomas et al. (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 32:995-1005
Rentz, Dorene M; Mormino, Elizabeth C; Papp, Kathryn V et al. (2017) Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging Behav 11:383-390
Tarrant, Sarah D; Bardach, Shoshana H; Bates, Kendra et al. (2017) The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord 31:141-145
Langa, Kenneth M; Larson, Eric B; Crimmins, Eileen M et al. (2017) A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA Intern Med 177:51-58
Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535
Marquié, Marta; Verwer, Eline E; Meltzer, Avery C et al. (2017) Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. Acta Neuropathol Commun 5:75

Showing the most recent 10 out of 490 publications